Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study

BACKGROUND AND OBJECTIVES: Idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation. Safety, pharmacokinetics and pharmacodynamics of idarucizumab were investigated in dabigatran-treated, middle-aged, elderly and renally impaired volunteers with characteris...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Pharmacokinet
Autori principali: Glund, Stephan, Stangier, Joachim, van Ryn, Joanne, Schmohl, Michael, Moschetti, Viktoria, Haazen, Wouter, De Smet, Marina, Gansser, Dietmar, Norris, Stephen, Lang, Benjamin, Reilly, Paul, Kreuzer, Jörg
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer International Publishing 2016
Soggetti:
Original Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5222901/
https://ncbi.nlm.nih.gov/pubmed/27317414
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-016-0417-0
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi